Transgene receives grant for hepatitis C vaccine
Transgene receives grant for hepatitis C vaccine
26th January 2006
By Staff Writer
France-based biopharmaceutical company Transgene has been awarded an E1.3
million for the development of its therapeutic vaccine candidate against
hepatitis C chronic infection.
The grant comes from the Lyon Biopole
Competitiveness Cluster (pole de competitivite), a French government scheme
designed to promote industrial growth in the country.
This funding is expected to total the E1.3 million over the next three years and
will cover 30% of the R&D costs for the program.
The grant aims at strengthening the development of Transgene's vaccine
candidate, TG4040, which is currently undergoing preclinical studies and should
enter phase I/II trial by mid-2006 to treat patients not responding to standard
therapy.
"We are extremely pleased to be among the very first projects selected by Lyon
Biopole and to receive government financial support for the development of our
innovative approach to treat patients chronically infected by hepatitis C,"
stated Philippe Archinard, CEO of Transgene.
http://www.pharmaceutical-business-review.com/article_news.asp?guid=A06A42EC-B2E\
E-4BF0-9A21-BEAFA9AA8152